Yinghong Gao (Yinghong Gao | LinkedIn; Yinghong Gao | Google Scholar) is a Venture Partner of Viva BioInnovator. She is responsible for the post investment management of multiple VBI portfolio companies. She is also heavily involved in deal sourcing and spearheading collaborations with external institutions and investment communities in the innovative drug discovery space. Prior to that she has extensive drug R&D and BD/licensing experience working with Neurocrine Biosciences, Arena Pharmaceticals, Merck KGaA and other biotech companies. She has contributed to the discovery of Neurocrine's GnRH antagonist ORILISSA® and Arena’s S1P modulator Etrasimod.